Financial Summary (All financials)
In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
Revenues | 19,629.0 | 18,236.0 | 16,785.0 | 18,372.0 | 17,408.0 | 15,264.0 | 14,522.0 | 16,249.0 |
Revenue growth | 7.6% | 8.6% | -8.6% | 5.5% | 14.0% | 5.1% | -10.6% | -8.4% |
Cost of goods sold | 11,549.0 | 10,730.0 | 9,793.0 | 10,557.0 | 9,976.0 | 8,833.0 | 8,260.0 | 9,241.0 |
Gross profit | 8,080.0 | 7,506.0 | 6,992.0 | 7,815.0 | 7,432.0 | 6,431.0 | 6,262.0 | 7,008.0 |
Gross margin | 41.2% | 41.2% | 41.7% | 42.5% | 42.7% | 42.1% | 43.1% | 43.1% |
Selling, general and administrative | 4,248.0 | 4,179.0 | 3,986.0 | 4,457.0 | 4,269.0 | 3,607.0 | 3,464.0 | 3,735.0 |
EBITA | 3,682.0 | 3,384.0 | 2,711.0 | 3,239.0 | 3,015.0 | 2,584.0 | 2,514.0 | 5,041.0 |
EBITA margin | 18.8% | 18.6% | 16.2% | 17.6% | 17.3% | 16.9% | 17.3% | 31.0% |
Amortization of intangibles | 563.0 | 470.0 | 369.0 | 359.0 | 314.0 | 222.0 | 177.0 | 174.0 |
EBIT | 3,119.0 | 2,914.0 | 2,342.0 | 2,880.0 | 2,701.0 | 2,362.0 | 2,337.0 | 4,867.0 |
EBIT margin | 15.9% | 16.0% | 14.0% | 15.7% | 15.5% | 15.5% | 16.1% | 30.0% |
Pre-tax income | 4,085.0 | 2,912.0 | 2,335.0 | 2,859.0 | 2,667.0 | 2,335.0 | 2,316.0 | 3,807.0 |
Income taxes | 855.0 | 585.0 | 345.0 | 531.0 | 443.0 | 660.0 | 697.0 | 1,267.0 |
Tax rate | 20.9% | 20.1% | 14.8% | 18.6% | 16.6% | 28.3% | 30.1% | 33.3% |
Earnings from continuing ops | 3,231.0 | 2,303.0 | 1,965.0 | 2,306.0 | 2,203.0 | 3,318.0 | 1,590.0 | 2,517.0 |
Earnings from discontinued ops | | | | | | -125.0 | 45.0 | 193.0 |
Net income | 3,231.0 | 2,303.0 | 1,965.0 | 2,306.0 | 2,203.0 | 3,193.0 | 1,635.0 | 2,710.0 |
Net margin | 16.5% | 12.6% | 11.7% | 12.6% | 12.7% | 20.9% | 11.3% | 16.7% |
|
Diluted EPS | $5.42 | $3.83 | $3.24 | $3.72 | $3.47 | $5.16 | $2.46 | $3.72 |
Shares outstanding (diluted) | 596.3 | 601.8 | 606.6 | 620.6 | 635.3 | 643.4 | 646.8 | 676.5 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|